iCARE 2.0: A Pilot Intervention of Dialectical Behavioural Therapy for Youth With Type 2 Diabetes.
NCT ID: NCT05107154
Last Updated: 2024-06-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
60 participants
INTERVENTIONAL
2022-11-21
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators have planned 2 pilots in order to address the uncertainties surrounding the planning of a larger definitive trial and allow adequate engagement and building of a meaningful traditional medicine component. These pilots will inform the development of a co-designed, feasible, and embraced Dialectical Behavioural Therapy (DBT) skills training and traditional teachings intervention, which is adequately powered to examine effectiveness on outcomes such as mental wellness, medication adherence, and improved glycemic control and renal function.
Research Aims: 1. Determine the recruitment, enrollment and adherence rates to the intervention. 2. Evaluate acceptability of the intervention using traditional qualitative methods and Indigenous world view methodology 3. Determine the estimated effect size required to power a large-scale DBT randomized control trial for the outcomes quality of life (primary), glycemic control and albuminuria (secondary).
Study Hypotheses: 1. The investigators hypothesize that a DBT intervention will be feasible on a local and National Platform and will be acceptable and embraced by youth with T2D as an important component of their management plan. 2. The investigators hypothesize that the additional of traditional medicine elements will increase the acceptability and adherence to DBT for Indigenous children.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diabetes Transition Coordinator Study
NCT06300047
Diabetes Intervention Program for Adolescents With Persistent High HA1c
NCT02212158
I-care: Stimulating Self-management in Patients With Type 2-diabetes
NCT01297049
Rowing Away From Diabetes
NCT02444156
Technology-Enabled Collaborative Care for Young Adults With Type 1 Diabetes and Diabetes Distress: A Feasibility Trial
NCT06804694
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Screening, Enrolment and Intervention Assignment: Research assistants will recruit participants from the Diabetes Education Resource for Children and Adolescents, located in the Community Services Building at the Health Science Center in Winnipeg, Manitoba. Participants currently enrolled in the iCARE Cohort, who have consented to be contacted about future studies and who meet eligibility requirements will also be approached to share information about this study. Interested participants will be screened utilizing a number of questionnaires and self-report measures in person (if allowable), via telephone, or on REDCap
Pilot 1 will be completed virtually through Zoom HealthCare.
The main outcome measures for the pilot trials were selected to inform the feasibility and sample size required for a larger RCT on a national scale. These include recruitment rates, retention rates, adherence to the intervention, retention for follow-up measurements, and satisfaction with the intervention. The investigators will also assess youth and parent experiences and perceptions of the intervention using inductive qualitative research upon completion of the 16-week trial.
The proposed intervention is mental health support intervention, therefore it does not include medication therapy or devices. The program is being delivered by trained clinical psychologist/psychology students.
Debriefing occurs throughout the intervention to assess for significant mental distress (including but not limited to weekly check-ins). Individual mental health concerns will be dealt with with as they arise. If at any point during the clinical research, clinicians judge the program is no longer beneficial or actively detrimental to an individual's health and wellbeing, the team has the right to end services and provide referrals and support for other treatment models.
Adverse events (AE) will be collected to document unfavorable changes in current health status of the research participant or any incident, experience or outcome that suggests that the research may place participants or others at a greater risk of harm (including physical, psychological, economic or social harm). The AE's that will be reported will include complications from the blood draw (syncopal episode, infection, excessive bleeding requiring medical attention), or events that could be related to completing the mental health questionnaires (emergency visit or crisis resource utilization or hospitalization for suicidal ideation, attempt). All deaths, regardless of cause will also be recorded for participants active in the study.
Sample Size Assessment
Sample size analysis showed that a full-scale trial would require 150 subjects (using a standardized effect size of 0.4 scale change in the self reported quality of life for an individual). The investigators chose to use 10% of this for each pilot (n=15) and added a control arm of n=15 for each pilot as well.
Quantitative Analytic Plan
For feasibility outcomes the investigators will be looking for a minimum 70% adherence (i.e. completing 11/16 sessions) in order to properly test the study hypothesis with a larger trial. A minimum 85% retention rate at follow-up (i.e. percentage of randomized participants that provide outcome measures at follow-up) is needed to protect the original randomization. For estimated effect size of the intervention the investigators will test for group-wise differences in the outcome measures using a repeated measures mixed effects regression model with a random subject effect to account for the within-subject correlations and repeated measures design with outcomes assessed at baseline and 16 weeks. Fixed effects will include treatment, time, and their interaction. An intention to treat strategy will be adopted for the final analysis. The analysis will be underpowered to test for effects for boys and girls separately, however sex as an interaction term in the analysis will be added.
Qualitative Analytic Plan
Youth \& parents/guardian from the DBT intervention arm of both pilot studies (n = 30) will participate in end-point semi-structured interviews of 45-minute duration, guided by Interpretive Description methodology. Interpretive description is a non-categorical applied research approach that seeks to generate understanding of clinically relevant phenomena in relation to its local context. An investigator (M.A) with extensive qualitative research experience will conduct all interviews. Interviews will be conducted via Zoom HealthCare or in-person if allowable. Questions will focus on perceptions of intervention delivery (e.g., duration, dose, timing, interventionist); content (e.g., domains); experiences - including emotional and cognitive responses; and intervention acceptability.
Audio recorded data will be transcribed verbatim and managed using NVivo software (version 1.0). Data from the first three transcripts will inform development of a coding framework which will be applied to subsequent interviews and iteratively revised upon identification of new conceptually distinct codes. Codes will be grouped into thematic clusters with supporting narrative excerpts. Thematic data will be used to refine what the investigators determine as modifiable domains of DBT.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dialectical Behavioural Therapy
Participants randomized to the Dialectical Behavioural Therapy (DBT) skills training intervention will receive a 90-minute DBT skills training session every week for 16 weeks total. The sessions will be facilitated by a health practitioner supervised by a clinical health psychologist with expertise in program development and DBT-adaptations for a variety of populations. Sessions for Pilot 1 will be delivered via Zoom HealthCare and in person if allowable. In-person sessions would be delivered at the Children's Hospital Research Institute of Manitoba. Pilot 2 will be adapted to address any additional needs uncovered through he qualitative assessment of Pilot 1. Traditional medicine components will be developed within the first 2 years of the grant by Indigenous researchers, patient and parent advisors, elders, and community advisory groups. These elements will be offered as an encouraged, yet optional component (additional modules) within the 16-week DBT intervention in Pilot 2.
Dialectical Behavioural Therapy
DBT skills training is organized into 5 specific modules designed to support skills needed to control emotional reactivity, including: Mindfulness, Distress Tolerance, Walking the Middle Path (a family-based module developed by our co-investigators specifically for teens), Emotion Regulation, and Interpersonal Effectiveness.
Control
Participants randomized to the control arm will receive standard medical care and clinical follow-up. Controls will be offered DBT after completion of Pilot 1 and 2. Participation will be optional.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dialectical Behavioural Therapy
DBT skills training is organized into 5 specific modules designed to support skills needed to control emotional reactivity, including: Mindfulness, Distress Tolerance, Walking the Middle Path (a family-based module developed by our co-investigators specifically for teens), Emotion Regulation, and Interpersonal Effectiveness.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* An additional thirty youths (14-22 years old) will be recruited to participate in Pilot 2.
Exclusion Criteria
* Ever cancer
* Other chronic illness associated with systemic inflammation (ex. Juvenile rheumatoid arthritis, Crohn's disease)
* Active psychotic disorder
* Past year suicide attempt or an active plan
* Self-reported substance/alcohol use disorder in past (1 year)
* Patient and/or caregiver unable or unwilling to provide voluntary informed assent/consent
* Currently pregnant (eligible at 3 months post-partum)
14 Years
22 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Dr. Brandy Wicklow
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Brandy Wicklow
Principle Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brandy Wicklow, MD MSc
Role: PRINCIPAL_INVESTIGATOR
University of Manitoba
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinic Y, Health Sciences Centre
Winnipeg, Manitoba, Canada
Diabetes Education Resource Centre for Adolescents Clinic, Health Sciences Centre
Winnipeg, Manitoba, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B2021:079
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.